Overview of Bandy Plus

Bandy Plus is a prescription-only, fixed-dose combination (FDC) medicine used to manage parasitic infections caused by helminths (worms). It is classified as a broad-spectrum anthelmintic agent, a pharmacological category specifically designed to expel or kill parasitic worms from the body. Supplied as an oral tablet for administration, this product represents a synthetic combination approach to anti-parasitic treatment. The use of this combination is clinically recognized for its effectiveness against co-infections, where a patient may be simultaneously infected with more than one type of parasite.

Quick Facts

Property	Description
Active Ingredients	Albendazole, Ivermectin
Form	Oral tablet
Pharmacological Class	Anthelmintic / Anti-parasitic agent
Type	Fixed-dose combination (FDC)
Origin	Synthetic compound

Active Ingredients and Composition of Bandy Plus

Bandy Plus contains the two principal active ingredients: Albendazole and Ivermectin. Albendazole belongs to the benzimidazole carbamate chemical class, while Ivermectin is classified as a macrocyclic lactone derivative. This formulation is a combination drug, strategically merging two distinct pharmaceutical compounds into a single dose to enhance therapeutic breadth.

The inclusion of two active components from different chemical families ensures a wider efficacy range against various parasitic species and life stages. For this dual-agent formulation, other popular trade names containing the same combination include Ivecop Plus and Zentel Plus.

What is the General Purpose of Bandy Plus?

The general purpose of Bandy Plus is to provide broad-spectrum anti-parasitic treatment through a powerful synergistic effect. This combination targets the parasite on two essential biological fronts: Albendazole works primarily by causing energy starvation through inhibiting the worm’s ability to absorb vital nutrients, while Ivermectin causes rapid physical paralysis by interfering with the parasite's nerve and muscle functions. By attacking both the metabolism and mobility of the parasite, this dual mechanism supports the effective, comprehensive clearance of parasitic organisms from the body. Both active ingredients are recognized as essential medicines for the control and elimination of various human helminthiases.

Regulatory References

view WHO Essential Medicines List

What side effects are possible with Bandy Plus?

Possible Side Effects and Safety Information

The official safety information for the Albendazole and Ivermectin combination (Bandy Plus) classifies adverse reactions according to frequency bands derived from clinical trials and post-marketing surveillance. The profile highlights potential effects across several System-Organ Classes (SOCs).

Common Adverse Reactions

Adverse effects listed as common in regulatory documents are generally transient and involve the nervous system (such as headache and dizziness) and the gastrointestinal system (including nausea, vomiting, abdominal pain, and diarrhea). Transient elevation of hepatic enzymes (liver transaminases) is also documented as a common finding.

Serious Adverse Reactions and Safety Constraints

The label documents rare but clinically significant safety concerns. Serious dermatological reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and severe hepatotoxicity (liver injury/hepatitis) are officially listed. Rare, severe disorders of the blood and lymphatic system, including agranulocytosis and pancytopenia, are also noted.

The medicine is officially contraindicated in women who are pregnant and should not be used by individuals with known hypersensitivity to the active ingredients or any excipient. A high-level caution is advised for patients with impaired hepatic function due to the metabolism of the active components.

Some adverse events may be more frequently observed at the beginning of treatment. In addition, the official regulatory text notes that reversible hair loss (alopecia) has been associated with prolonged or high-dose courses of the Albendazole component.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of the fixed-dose combination Bandy Plus (Albendazole/Ivermectin) is officially associated with severe systemic toxicity and necessitates immediate medical attention. Documented clinical manifestations primarily affect the gastrointestinal and central nervous systems. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal pain. More critically, high exposure can lead to neurological signs such as confusion, tremors, headache, and altered mental status, potentially progressing to severe outcomes like seizures, coma, and death. Cardiovascular complications like hypotension and tachycardia are also recognized.

Regulatory guidance mandates that individuals must seek immediate medical treatment or contact the Poison Control Center for a suspected overdose. Emergency services must be called immediately if the person has collapsed, is having a seizure, or cannot be awakened. Treatment is supportive, as no specific antidote is known for this combination. Management includes symptomatic and supportive care, along with procedural steps like gastric lavage. Due to the Albendazole component, monitoring of blood counts is a critical consideration, particularly for patients with pre-existing hepatic dysfunction, owing to the documented risk of bone marrow suppression.

Therapeutic Uses of Bandy Plus

Quick Facts: Uses of Bandy Plus

Targeted Conditions: Management of certain parasitic worm infections.
Infections Addressed: Used for treatment of infections caused by various nematodes, including roundworms, hookworms, threadworms, and whipworms.
Additional Application: May be indicated in the treatment regimen for lymphatic filariasis (elephantiasis).

Bandy Plus is a medication used to treat a range of infections caused by parasitic worms, often referred to as soil-transmitted helminths (STH). The primary therapeutic application is the management of intestinal parasitic infections, including those caused by Ascaris lumbricoides (large roundworm), Necator americanus and Ancylostoma duodenale (hookworms), and Trichuris trichiura (whipworm).

The medication is also a therapeutic option for addressing certain infections caused by Strongyloides stercoralis (threadworm). Furthermore, it is a component of treatment protocols for lymphatic filariasis, a condition characterized by the presence of microfilariae in the blood, which may lead to abnormal enlargement of body parts.

Regulatory References

EMA therapeutic overview on Ivermectin/Albendazole

Eligibility and Restrictions for Use

The eligibility for using the fixed-dose combination Bandy Plus is strictly governed by official regulatory documentation, defining specific populations who are permitted, restricted, or prohibited from treatment.

Absolute Contraindications: The medicine must not be used by women who are pregnant or who intend to conceive. Due to associated risks, women of reproductive potential are required to use effective contraception before, during, and for one month following the last dose. Use is also strictly contraindicated in any patient with a known hypersensitivity to the active ingredients, Albendazole or Ivermectin, or to the related benzimidazole class of drugs.

Age and Population Restrictions: Bandy Plus is indicated only for adults, adolescents, and children five years of age or older. It is generally not recommended for children weighing less than 15 kilograms.

Conditional Use and Monitoring: Use is restricted and requires close clinical monitoring in patients with pre-existing liver dysfunction or abnormal liver function test results. For lactating women, treatment is conditional and specifically not recommended during the first week after giving birth. Furthermore, individuals with suspected or confirmed high levels of Loa loa microfilariae are subject to use restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bandy Plus, which contains the active ingredients Albendazole and Ivermectin, has documented interactions that primarily affect the plasma levels of its active metabolite, Albendazole sulfoxide, or lead to pharmacodynamic reinforcement.

Pharmacokinetic Exposure Alterations

Co-administration with certain medicines can significantly alter the systemic exposure of the drug, as documented in regulatory labeling.

Interacting Substance	Official Interaction Outcome	Classification
Dexamethasone	Increases plasma exposure (AUC) of Albendazole sulfoxide by approximately 56%.	Exposure-altering
Praziquantel	Increases maximum plasma concentration and exposure (AUC) of Albendazole sulfoxide.	Exposure-altering
Phenytoin / Carbamazepine	Decreases plasma levels of Albendazole sulfoxide, potentially reducing efficacy.	Metabolic
Cimetidine	Increases the plasma concentration of Albendazole sulfoxide.	Metabolic

Pharmacodynamic and Substance Interactions

Official regulatory information also notes the potential for additive effects and specific interactions with food and other substances. Ivermectin co-administration with Warfarin has been associated with an increased International Normalized Ratio (INR), indicating a risk of enhanced anticoagulant activity. Albendazole combined with other myelosuppressive agents carries an additive risk of bone marrow suppression.

Furthermore, the official drug label for Albendazole notes a clinically significant drug–food interaction where taking the medicine with a high-fat meal significantly increases the systemic absorption and plasma levels of the active metabolite. No medicinal products are formally listed as contraindicated for co-administration in the regulatory labels.

Mechanism of Action

The mechanism of action of Bandy Plus relies on two distinct and cooperative biological actions to disrupt essential survival processes in the target organisms.

Disrupting Energy and Structural Integrity

One component acts by targeting the parasite’s beta-tubulin protein, which is vital for building internal microtubules. By preventing the assembly of these structures, the mechanism blocks the parasite’s ability to absorb essential nutrients, particularly glucose. This leads to the depletion of energy stores and structural failure, rapidly compromising the organism's metabolic function.

Inducing Neuromuscular Paralysis

The second component targets the parasite's nervous system by acting as an agonist at glutamate-gated chloride channels (GluCl). Activating these channels causes a massive influx of chloride ions, which hyperpolarizes the nerve and muscle cells. This resulting cascade causes immediate and sustained paralysis of the parasite's muscles and feeding apparatus. This physiological change prevents the parasite from maintaining its position, moving, or feeding, which results in the organism being functionally immobilized.

Achieving Synergistic Effect

These two mechanisms work together to attack the parasite on multiple fronts: metabolic starvation and neuromuscular shutdown. This comprehensive attack profile influences the observable physiological effects by simultaneously attacking both the parasite's metabolism and neuromuscular function.

Dosage and Administration Information

How to Use Bandy Plus

Bandy Plus, the fixed-dose combination (FDC) of albendazole and ivermectin, is an oral medicine whose administration is governed by established protocols for the management of parasitic worm infections. Treatment should be started under the supervision of a healthcare professional with experience in helminth infections and must follow official public health guidance.

Dosing and Administration

The medicine is supplied as an orodispersible tablet intended for oral use. The dose should be administered with or immediately after a meal to enhance the absorption of the medicine's components. The orodispersible tablet should be placed on the tongue, where it rapidly dissolves upon contact with saliva. In instances where a patient has difficulty swallowing, the dissolved tablet can be given through a feeding tube.

Usage Pattern	Dosing Regimen (Albendazole/Ivermectin)	Frequency and Duration
Mass Drug Administration (MDA)	One fixed-dose tablet (e.g., 400 mg/9 mg or 400 mg/18 mg)	Single dose, typically administered once a year (or every 6 months) as per national health programs.
Individual Short-Course	One fixed-dose tablet (e.g., 400 mg/9 mg or 400 mg/18 mg)	Once daily for three consecutive days for specific infections.

Population-Specific Use

Bandy Plus is indicated for use in adults, adolescents, and children aged 5 years and older. The specific strength of the tablet used in a Mass Drug Administration setting may be subject to regional differences based on age and local guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bandy Plus (Albendazole/Ivermectin FDC)

Evidence for Use in Intestinal Worm Infections

The primary research for the Albendazole/Ivermectin fixed-dose combination (FDC) involves studies focusing on infections caused by soil-transmitted helminths (STH), commonly known as intestinal worms. The majority of this evidence is derived from short-term Randomized Controlled Trials (RCTs) conducted in areas where these infections are prevalent; these trials often used Albendazole monotherapy as a comparator. These studies research examined parasitological outcomes by measuring the absence or change in the number of parasite eggs found in stool samples before and after administration.

Evidence Structure for Trichuriasis (Whipworm)

Research on whipworm infection, or Trichuriasis, involved short-term RCTs, predominantly including school-aged children, which was studied for how the combination measured against Albendazole monotherapy. These studies monitored the measured clearance rates (absence of eggs) and the Egg Reduction Rate after a defined time interval. Findings from multiple trials describe patterns where the combination's measured parasitological outcome for this specific parasite differed from the measurements reported for Albendazole used alone. The consistency of the reported findings for this research is designated as High among the available studies, but the results apply only to the populations studied in those trials.

Evidence Structure for Hookworm and Ascariasis

For infections caused by hookworm and roundworm (Ascariasis), studies examined the same metrics: Cure Rate and Egg Reduction Rate, often within the same multi-species trials. Studies report how symptoms evolved in the observed populations, with measurements for roundworm often being similar to the metrics reported for Albendazole used alone, a single agent that is already known to be associated with high measured metrics for this parasite. For hookworm, data show patterns related to different regimens (e.g., single-day versus multi-day administration) with findings that were mixed or inconsistent when compared to the Albendazole monotherapy used as a comparator. The evidence level for research on these two parasites appears to be categorized as Moderate.

Research Evidence for Strongyloidiasis (Threadworm) and Lymphatic Filariasis

Research on the combination was studied for other specific parasitic conditions, namely Strongyloidiasis (threadworm) and Lymphatic Filariasis (LF). For Strongyloidiasis, the available research was evaluated in RCTs that included participants co-infected with threadworm, where studies research examined parasitological outcomes, such as the absence of larvae in stool samples. For Lymphatic Filariasis, the FDC was evaluated in the context of large-scale public health and Mass Drug Administration (MDA) programs. The research for this condition is characterized by studies that monitored microfilariae (larvae) prevalence and density in the blood over intermediate and long-term periods.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Bandy Plus (FAQ)

Q: How quickly does Bandy Plus start working after taking it?

A: Official regulatory information on the medicine's components indicates the time it takes for the active ingredients to be absorbed into the bloodstream. The active Albendazole metabolite typically reaches its highest concentration in the blood within two to five hours. The Ivermectin component reaches its peak concentration around 4.5 hours after being taken.

Q: How long does the effect of one dose of Bandy Plus last?

A: Based on pharmacokinetic data, which describes how the medicine moves through the body, the active Albendazole component typically has an elimination half-life of 8 to 12 hours. The Ivermectin component is noted to be gradually excreted over an estimated period, which may take up to 12 days.

Q: Does Bandy Plus make you feel tired or drowsy?

A: Clinical trial data included in the product information reports nervous system effects such as somnolence (drowsiness) and asthenia (fatigue) as possible side effects. These effects were reported with a low frequency.

Q: Does Bandy Plus interact with alcohol?

A: Regulatory information indicates that co-administering the medicine with alcohol may lead to the intensification of certain side effects. These potential effects may include the intensification of certain side effects such as dizziness, sleepiness, and symptoms affecting the stomach.

Q: Are there specific instructions for what to do if an allergic reaction to Bandy Plus occurs?

A: Regulatory safety information describes signs of a serious allergic reaction and notes that immediate emergency medical attention should be sought if these occur. These signs can include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

Q: How long after taking Bandy Plus can I expect results?

A: Official trial summaries often measure objective outcomes, such as parasite clearance, at defined intervals after the full course of treatment. For example, some studies evaluate the result 21 days after the final dose, rather than providing a specific time for when a person may feel subjective relief from symptoms.

Q: Is Bandy Plus the same as [Commonly named component drug 1]?

A: Bandy Plus is a fixed-dose combination (FDC) medicine, meaning it contains two active ingredients: Albendazole and Ivermectin. This makes it different from a product that contains only one active component (a monotherapy).

Q: Why do people take Bandy Plus instead of just [Commonly named component drug 2]?

A: The combination is used because clinical evidence describes improved efficacy against certain parasitic infections (like T. trichiura) and a broader spectrum of coverage compared to single-agent treatments used alone.

Q: Is Bandy Plus considered a strong medicine?

A: Regulatory documents classify Bandy Plus as an anthelmintic agent, which is a pharmacological category specifically designed to kill or expel parasitic worms. The two active components work synergistically, meaning they work together, to achieve their intended effect.

Q: Can elderly patients take Bandy Plus?

A: Official guidance indicates the medicine is for use in adults, adolescents, and children aged five years and older. No specific warnings or dosage adjustments are detailed solely for the geriatric population in available regulatory summaries.

Q: Is Bandy Plus available without a prescription in some countries?

A: The medicine is classified as a prescription-only drug. However, its availability and required prescription status are subject to the national regulations and rules of each individual country.

Q: Why is Bandy Plus sometimes prescribed for things other than parasites?

A: The official regulatory purpose of Bandy Plus, as detailed in its product label, is to manage parasitic infections caused by helminths (worms). It is also listed by the World Health Organization (WHO) as an essential medicine for the control of human helminthiases.

Q: Can I take Bandy Plus if I have a history of seizures?

A: Regulatory information notes that seizures have been reported rarely following the use of Ivermectin. Patients with certain infections, such as neurocysticercosis, may require high-level caution and additional therapy due to potential neurological effects.

Q: Can Bandy Plus cause allergic reactions?

A: The medicine is officially contraindicated (must not be used) in patients with a known hypersensitivity (allergic reaction) to either of the active ingredients (Albendazole or Ivermectin) or to any component of the formulation.

Q: Do I need to change my diet while taking Bandy Plus?

A: Official instructions note that administering the medicine with a meal, particularly a high-fat meal, is associated with a significant increase in the systemic absorption of the active component.

Q: What happens if a child accidentally swallows too much Bandy Plus?

A: Regulatory guidelines describe the need for symptomatic therapy and general supportive measures in the event of a suspected overdose. There is no specific antidote available for the active components.

Q: Is it safe to drive or operate machinery after taking Bandy Plus?

A: Regulatory information lists dizziness, vertigo, and somnolence (drowsiness) as possible side effects. These central nervous system effects may impact a person's ability to drive or safely operate machinery.

Q: Does Bandy Plus have different names in other countries?

A: Yes, the product name may vary by region or country. The fixed-dose combination is subject to separate review and approval by national regulatory agencies globally, which often results in different trade names being used.

Q: Are there any known issues with taking Bandy Plus for multiple days?

A: Regulatory documents specify use in both single-dose and multiple-day regimens for different indications. Safety concerns related to prolonged use are generally managed through routine blood count and liver enzyme monitoring, as described in the warnings.

Q: What research is currently being done on Bandy Plus?

A: The fixed-dose combination has been the subject of research protocols, often supported by global public health initiatives, that examine safety and effectiveness in mass drug administration campaigns.

How should Bandy Plus be stored and disposed of?

The storage and disposal of Bandy Plus (albendazole/ivermectin) tablets must comply strictly with official regulatory requirements to ensure product stability and public safety.

Official Storage Requirements

Condition	Regulatory Specification
Temperature	Store at Controlled Room Temperature, 25 C (77 F), with permitted excursions up to 30 C (86 F).
Protection	Keep in the original package to protect the contents from light and moisture.
Security	The medication must be kept out of the sight and reach of children and pets, ideally in a secured or locked location.

Disposal Instructions

Unused or expired Bandy Plus must be disposed of in accordance with local requirements for pharmaceutical waste, such as official drug take-back programs. Disposal must prioritize environmental protection, which means the product should not contaminate water and is generally prohibited from being flushed down the toilet or poured into any drain.

Bandy Plus